Literature DB >> 24476315

Where does a Staphylococcus aureus vaccine stand?

V G Fowler1, R A Proctor.   

Abstract

In this review, we examine the current status of Staphylococcus aureus vaccine development and the prospects for future vaccines. Examination of the clinical trials to date show that murine models have not predicted success in humans for active or passive immunization. A key factor in the failure to develop a vaccine to prevent S. aureus infections comes from our relatively limited knowledge of human protective immunity. More recent reports on the elements of the human immune response to staphylococci are analysed. In addition, there is some controversy concerning the role of antibodies for protecting humans, and these data are reviewed. From a review of the current state of understanding of staphylococcal immunity, a working model is proposed. Some new work has provided some initial candidate biomarker(s) to predict outcomes of invasive infections and to predict the efficacy of antibiotic therapy in humans. We conclude by looking to the future through the perspective of lessons gleaned from the clinical vaccine trials.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Biomarker; Staphylococcus aureus; outcome; protective immunity; review; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24476315      PMCID: PMC4067250          DOI: 10.1111/1469-0691.12570

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  92 in total

Review 1.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

2.  Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome.

Authors:  Thu A Chau; Michelle L McCully; William Brintnell; Gary An; Katherine J Kasper; Enrique D Vinés; Paul Kubes; S M Mansour Haeryfar; John K McCormick; Ewa Cairns; David E Heinrichs; Joaquín Madrenas
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

3.  High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital.

Authors:  S Quilty; G Kwok; K Hajkowicz; B Currie
Journal:  Intern Med J       Date:  2009-08       Impact factor: 2.048

4.  Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections.

Authors:  Rajan P Adhikari; Adebola O Ajao; M Javad Aman; Hatice Karauzum; Jawad Sarwar; Alison D Lydecker; J Kristie Johnson; Chinh Nguyen; Wilbur H Chen; Mary-Claire Roghmann
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.

Authors:  Vance G Fowler; Keith B Allen; Edson D Moreira; Moustafa Moustafa; Frank Isgro; Helen W Boucher; G Ralph Corey; Yehuda Carmeli; Robert Betts; Jonathan S Hartzel; Ivan S F Chan; Tessie B McNeely; Nicholas A Kartsonis; Dalya Guris; Matthew T Onorato; Steven S Smugar; Mark J DiNubile; Ajoke Sobanjo-ter Meulen
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

6.  N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor.

Authors:  Pieter-Jan Haas; Carla J C de Haas; Wendy Kleibeuker; Miriam J J G Poppelier; Kok P M van Kessel; John A W Kruijtzer; Rob M J Liskamp; Jos A G van Strijp
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

7.  Characterization of infecting strains and superantigen-neutralizing antibodies in Staphylococcus aureus bacteremia.

Authors:  Dorothee Grumann; Eeva Ruotsalainen; Julia Kolata; Pentti Kuusela; Asko Järvinen; Vesa P Kontinen; Barbara M Bröker; Silva Holtfreter
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

Review 8.  Staphylococcal vaccines and immunotherapies.

Authors:  Adam C Schaffer; Jean C Lee
Journal:  Infect Dis Clin North Am       Date:  2009-03       Impact factor: 5.982

Review 9.  Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review.

Authors:  Diana E Thomas; Elizabeth J Elliott
Journal:  BMC Public Health       Date:  2013-09-03       Impact factor: 3.295

10.  Effect of socioeconomic status on mortality after bacteremia in working-age patients. A Danish population-based cohort study.

Authors:  Kristoffer Koch; Mette Nørgaard; Henrik Carl Schønheyder; Reimar Wernich Thomsen; Mette Søgaard
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more
  110 in total

1.  Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureus.

Authors:  Maite Villanueva; Ambre Jousselin; Kristoffer T Baek; Julien Prados; Diego O Andrey; Adriana Renzoni; Hanne Ingmer; Dorte Frees; William L Kelley
Journal:  J Bacteriol       Date:  2016-09-09       Impact factor: 3.490

2.  A microscale, full-thickness, human skin on a chip assay simulating neutrophil responses to skin infection and antibiotic treatments.

Authors:  Jae Jung Kim; Felix Ellett; Carina N Thomas; Fatemeh Jalali; R Rox Anderson; Daniel Irimia; Adam B Raff
Journal:  Lab Chip       Date:  2019-09-10       Impact factor: 6.799

3.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Clonally expanded γδ T cells protect against Staphylococcus aureus skin reinfection.

Authors:  Carly A Dillen; Bret L Pinsker; Alina I Marusina; Alexander A Merleev; Orly N Farber; Haiyun Liu; Nathan K Archer; Da B Lee; Yu Wang; Roger V Ortines; Steven K Lee; Mark C Marchitto; Shuting S Cai; Alyssa G Ashbaugh; Larissa S May; Steven M Holland; Alexandra F Freeman; Loren G Miller; Michael R Yeaman; Scott I Simon; Joshua D Milner; Emanual Maverakis; Lloyd S Miller
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

Review 5.  Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection.

Authors:  Ya-Ping Ko; Matthew J Flick
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

6.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

7.  Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein.

Authors:  Hang Yang; Jingjing Xu; Wuyou Li; Shujuan Wang; Junhua Li; Junping Yu; Yuhong Li; Hongping Wei
Journal:  EMBO J       Date:  2018-07-23       Impact factor: 11.598

8.  Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.

Authors:  Assaf Raz; Anna Serrano; Maneesha Thaker; Tricia Alston; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.

Authors:  Michael R Yeaman; Scott G Filler; Siyang Chaili; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John P Hennessey; Yue Fu; Clint S Schmidt; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

10.  Surface Glycopolymers Are Crucial for In Vitro Anti-Wall Teichoic Acid IgG-Mediated Complement Activation and Opsonophagocytosis of Staphylococcus aureus.

Authors:  Jong-Ho Lee; Na-Hyang Kim; Volker Winstel; Kenji Kurokawa; Jesper Larsen; Jang-Hyun An; Adnan Khan; Min-Young Seong; Min Ja Lee; Paal Skytt Andersen; Andreas Peschel; Bok Luel Lee
Journal:  Infect Immun       Date:  2015-08-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.